Hyperlipoproteinemias:
Indications for: LEQVIO
Adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C.
Limitations of Use:
The effect on cardiovascular morbidity and mortality has not been determined.
Adult Dosage:
Give by SC inj into abdomen, thigh, or upper arm. Initially 284mg as a single inj, repeat at 3 months, and then every 6 months. Measure LDL-lowering effect as early as 30 days after initiation and anytime thereafter.
Children Dosage:
Not established.
LEQVIO Warnings/Precautions:
Do not inject into areas of active skin disease or injury (eg, sunburns, skin rashes, inflammation, skin infections). ESRD. Severe hepatic impairment. Pregnancy: avoid. Nursing mothers.
LEQVIO Classification:
Small interfering RNA (siRNA).
Adverse Reactions:
Inj site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity, dyspnea.
Generic Drug Availability:
NO
How Supplied:
Single-dose prefilled syringe—1
